High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
about
The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular diseaseAdjunctive antioxidants for bipolar disorderEffect of allopurinol in chronic kidney disease progression and cardiovascular riskUric acid in metabolic syndrome: From an innocent bystander to a central playerThe discovery of hypertension: evolving views on the role of the kidneys, and current hot topicsUric Acid as a Marker of Kidney Disease: Review of the Current LiteratureAre either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisalRole of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic SteatohepatitisUntargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in miceAllopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials.Gout and the risk for incident heart failure and systolic dysfunction.Effect of allopurinol on blood pressure: a systematic review and meta-analysis.Distinct risk factors of atrial fibrillation in patients with and without coronary artery disease: a cross-sectional analysis of the BOREAS-CAG Registry data.The role of endothelial cell injury in thrombotic microangiopathy.Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort.Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort studyHyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data.The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of AtherosclerosisCausal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study.Uric acid does not affect the acetylcholine-induced relaxation of aorta from normotensive and deoxycorticosterone acetate-salt hypertensive rats.Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trialThe conundrum of hyperuricemia, metabolic syndrome, and renal disease.Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study.Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men.Sugar, uric acid, and the etiology of diabetes and obesity.Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS.Comorbidities in patients with crystal diseases and hyperuricemia.Allopurinol initiation and all-cause mortality in the general population.Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4.Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease.Impact of allopurinol use on urate concentration and cardiovascular outcomeThe pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortalityHypothesis: could excessive fructose intake and uric acid cause type 2 diabetes?Comparative study of renal protective effects of allopurinol and N-acetyl-cysteine on contrast induced nephropathy in patients undergoing cardiac catheterizationAllopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross-sectional study.Reactive oxygen species in cardiovascular disease.Allopurinol reduces the lethality associated with acute renal failure induced by Crotalus durissus terrificus snake venom: comparison with probenecid.Uric acid as a mediator of diabetic nephropathy.Dose-dependent effects of allopurinol on human foreskin fibroblast cells and human umbilical vein endothelial cells under hypoxia
P2860
Q21342788-4B1945B5-C9F0-470D-A125-D7B069DD1C90Q24198987-84C13DE6-2A98-4FEF-A25A-21645EB077A7Q24630327-3088C82A-D024-48DE-835F-072FB0B3C3D1Q26772053-5938D3BA-854B-4D2F-A151-4F1623DD28E6Q26830489-B2726E71-4044-474F-9C4F-E4F4F9568833Q26849588-2128CB9D-13BF-4958-8236-C35C4E44D9F9Q26862468-BC1EE625-2B22-435E-BE9C-3CE59A43CFAAQ28354735-E8459AF3-6D05-4475-A0C5-DABAF3B01413Q28480520-8A3556E2-5BC1-43F3-9D56-49DA24F78F15Q30248398-2F6C544A-7C03-4989-8CDC-452F33F57FABQ30505423-81A5EE22-0355-4EA5-923A-30D5D6C93F28Q31118679-5CD6CD25-2BD5-4BB6-AA52-6A1871560FC8Q31156918-A92BA1ED-3C49-4C14-98FE-CF87BFF6F274Q33391882-10FA5F6D-A973-411A-8182-6F39AD733A7BQ33701688-686CB37C-7C0B-4DD1-A518-D9F416967EB9Q33712386-B3E991EC-5702-4A58-82EB-529C954CBF8DQ33784030-1B29C39C-6ACD-498A-AC4A-D4E982118B77Q33838927-0899560D-BADD-4389-B3D4-931E68BF121DQ33887961-00D83379-3843-4514-86CA-E8FAFCE84D3AQ33890860-6F0FF5A0-91A9-4A2E-A937-903F3BCB9C19Q33935192-D0D006B8-3A61-4EA7-A829-C4E084CE3683Q33956635-3B306AA9-0C4D-48DD-9BAC-3BDBB0E8425BQ34005350-BC962104-6494-45A4-A2A3-ACC856089B59Q34029936-CB79C5A6-BB98-4BBC-8702-1E14E12E00DCQ34038315-224CF381-3DD4-44B2-ABA6-A36BA14EB9A8Q34100586-D9043A39-1488-4BD9-B04C-2A573AD91082Q34157725-34CB4E4B-1967-417C-B8FE-58BB5B186B18Q34466066-6DC57317-A0C4-4CD2-BA5F-25334785807DQ34596040-91A6B8CF-C07F-4143-A118-7F5DA6E1A45DQ34724943-1482EB36-9FB1-4DCB-9524-C2FCCA9C1DE2Q34830158-0D2123AA-6995-49AF-A464-AF05DE5029AAQ34877729-D209E025-AEE2-40AB-A101-EF70C7D5FC46Q34924188-53058114-9C62-4239-8F90-1C156506765CQ35046376-E3342CD6-575A-4A29-AD40-09F62BB639C4Q35108913-B09F89FC-CD95-4787-B741-EC93709294CEQ35121532-93AF6EE2-B1C7-45BD-BBFD-759331BB0164Q35165194-ED83FBC5-4F34-4F46-9101-9029F1A62D60Q35198815-E997EABB-2480-4D1D-B59A-111BD1249EC5Q35393446-F68535B9-692D-4A89-9923-9B31943B0180Q35592005-FC5A7905-4EEF-4771-B05E-C916D976A111
P2860
High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
High-dose allopurinol improves ...... and not by lowering uric acid.
@ast
High-dose allopurinol improves ...... and not by lowering uric acid.
@en
High-dose allopurinol improves ...... and not by lowering uric acid.
@nl
type
label
High-dose allopurinol improves ...... and not by lowering uric acid.
@ast
High-dose allopurinol improves ...... and not by lowering uric acid.
@en
High-dose allopurinol improves ...... and not by lowering uric acid.
@nl
prefLabel
High-dose allopurinol improves ...... and not by lowering uric acid.
@ast
High-dose allopurinol improves ...... and not by lowering uric acid.
@en
High-dose allopurinol improves ...... and not by lowering uric acid.
@nl
P2093
P1433
P1476
High-dose allopurinol improves ...... and not by lowering uric acid.
@en
P2093
Elaine Carr
Jacob George
Justine Davies
P304
P356
10.1161/CIRCULATIONAHA.106.651117
P407
P577
2006-11-27T00:00:00Z